和黃醫藥(00013.HK)：沃瑞沙® 和泰瑞沙® 的聯合療法在泰瑞沙®治療後疾病進展的MET驅動的EGFR突變肺癌患者中顯示出具有統計學和臨床意義的無進展生存期和總生存期改善

智通財經

14小時前

【和黃醫藥(00013.HK)：沃瑞沙® 和泰瑞沙® 的聯合療法在泰瑞沙®治療後疾病進展的MET驅動的EGFR突變肺癌患者中顯示出具有統計學和臨床意義的無進展生存期和總生存期改善】智通財經APP訊，和黃醫藥(00013.HK)發布公告，沃瑞沙®(ORPATHYS®，賽沃替尼/ savolitinib)和泰瑞沙®(TAGRISSO®，奧希替尼/ osimertinib)的聯合療法對比鉑類雙藥化療用於治療表皮生長因子受體(EGFR)突變非小細胞肺癌患者的SAFFRON III期研究取得積極的頂線結果，顯示出具有統計學和臨床意義的無進展生存期(PFS)和總生存期(OS)改善。研究中患者的腫瘤伴有高水平的MET過表達或擴增，並且既往曾接受過泰瑞沙®治療後疾病進展。

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hant/news/2660590105"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2660590105\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2660590105?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2026-08-17 08:18","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2660590105","market":"us","top_or_hot":-1,"title":"和黃醫藥(00013.HK)：沃瑞沙® 和泰瑞沙® 的聯合療法在泰瑞沙®治療後疾病進展的MET驅動的EGFR突變肺癌患者中顯示出具有統計學和臨床意義的無進展生存期和總生存期改善","media":"智通財經","content":"<html><body><div>\n<div>\n<b>【和黃醫藥(00013.HK)：沃瑞沙® 和泰瑞沙® 的聯合療法在泰瑞沙®治療後疾病進展的MET驅動的EGFR突變肺癌患者中顯示出具有統計學和臨床意義的無進展生存期和總生存期改善】</b>智通財經APP訊，和黃醫藥(00013.HK)發布公告，沃瑞沙®(ORPATHYS®，賽沃替尼/ \n\nsavolitinib)和泰瑞沙®(TAGRISSO®，奧希替尼/ \n\nosimertinib)的聯合療法對比鉑類雙藥化療用於治療表皮生長因子受體(EGFR)突變非小細胞肺癌患者的SAFFRON \n\nIII期研究取得積極的頂線結果，顯示出具有統計學和臨床意義的無進展生存期(PFS)和總生存期(OS)改善。研究中患者的腫瘤伴有高水平的MET過表達或擴增，並且既往曾接受過泰瑞沙®治療後疾病進展。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>和黃醫藥(00013.HK)：沃瑞沙® 和泰瑞沙® 的聯合療法在泰瑞沙®治療後疾病進展的MET驅動的EGFR突變肺癌患者中顯示出具有統計學和臨床意義的無進展生存期和總生存期改善</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n和黃醫藥(00013.HK)：沃瑞沙® 和泰瑞沙® 的聯合療法在泰瑞沙®治療後疾病進展的MET驅動的EGFR突變肺癌患者中顯示出具有統計學和臨床意義的無進展生存期和總生存期改善\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">智通財經</strong><span class=\"h-time small\">2026-08-17 08:18</span>\n</p>\n</h4>\n</header>\n<article>\n<html><body><div>\n<div>\n<b>【和黃醫藥(00013.HK)：沃瑞沙® 和泰瑞沙® 的聯合療法在泰瑞沙®治療後疾病進展的MET驅動的EGFR突變肺癌患者中顯示出具有統計學和臨床意義的無進展生存期和總生存期改善】</b>智通財經APP訊，和黃醫藥(00013.HK)發布公告，沃瑞沙®(ORPATHYS®，賽沃替尼/ \n\nsavolitinib)和泰瑞沙®(TAGRISSO®，奧希替尼/ \n\nosimertinib)的聯合療法對比鉑類雙藥化療用於治療表皮生長因子受體(EGFR)突變非小細胞肺癌患者的SAFFRON \n\nIII期研究取得積極的頂線結果，顯示出具有統計學和臨床意義的無進展生存期(PFS)和總生存期(OS)改善。研究中患者的腫瘤伴有高水平的MET過表達或擴增，並且既往曾接受過泰瑞沙®治療後疾病進展。                </div>\n</div></body></html>\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">智通財經</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1989772840.SGD","symbol_name":"CPR Invest - Climate Action A2 Acc SGD-H","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2660590105","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2660590105","pubTimestamp":1786925918,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【和黃醫藥(00013.HK)：沃瑞沙® 和泰瑞沙® 的聯合療法在泰瑞沙®治療後疾病進展的MET驅動的EGFR突變肺癌患者中顯示出具有統計學和臨床意義的無進展生存期和總生存期改善】智通財經APP訊，和","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","HCM":"和黄医药","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","BK4007":"制药","MET":"大都会人寿","BK4531":"中概回港概念","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1496350502.SGD":"FRANKLIN DIVERSIFIED DYNAMIC \"A\" (SGDHDG) ACC","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4162":"人寿与健康保险"},"translate_title":"Chi-Med (00013.HK): Vorisha ® And Teresa ® The combination therapy in Teresa ® Statistically and clinically significant improvements in progression-free survival and overall survival were shown in patients with MET-driven EGFR-mutated lung cancer with disease progression after treatment","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MET":1.5,"HCM":1.5},"content_text":"【和黃醫藥(00013.HK)：沃瑞沙® 和泰瑞沙® 的聯合療法在泰瑞沙®治療後疾病進展的MET驅動的EGFR突變肺癌患者中顯示出具有統計學和臨床意義的無進展生存期和總生存期改善】智通財經APP訊，和黃醫藥(00013.HK)發布公告，沃瑞沙®(ORPATHYS®，賽沃替尼/ \n\nsavolitinib)和泰瑞沙®(TAGRISSO®，奧希替尼/ \n\nosimertinib)的聯合療法對比鉑類雙藥化療用於治療表皮生長因子受體(EGFR)突變非小細胞肺癌患者的SAFFRON \n\nIII期研究取得積極的頂線結果，顯示出具有統計學和臨床意義的無進展生存期(PFS)和總生存期(OS)改善。研究中患者的腫瘤伴有高水平的MET過表達或擴增，並且既往曾接受過泰瑞沙®治療後疾病進展。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}